伏雷洛辛（CAS：175414-77-4），又称SNS-595或AG-7352，是一种新型萘啶衍生物，结构上与喹诺酮类抗生素相关，而喹诺酮类此前未用于肿瘤学领域。伏雷洛辛通过嵌入DNA并抑制拓扑异构酶II发挥抗肿瘤活性，进而导致DNA损伤和细胞凋亡。体外实验中，伏雷洛辛对多种肿瘤细胞系表现出强效抗增殖作用，IC50值介于0.04至0.97μM之间，包括过表达P-糖蛋白的细胞系。体内实验中，它在异种移植模型中以剂量依赖性方式抑制肿瘤生长。目前，伏雷洛辛治疗卵巢癌和急性髓系白血病的潜力正处于研究阶段。

参考文献：

[1] Tsuzuki Y, Tomita K, Shibamori K, Sato Y, Kashimoto S, Chiba K. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem.2004;47(8):2097-109.

[2] Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009;64(1):53-65.

[3] Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res. 2010;16(7):2167-75.